nach oben

Erschienen in:

01.08.2012 | PRECLINICAL STUDIES

The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma

verfasst von: Juliana Romanini, Tânia R. Mielcke, Paulo C. Leal, Cláudia P. Figueiredo, João B. Calixto, Fernanda B. Morrone, Eraldo L. Batista Jr, Maria M. Campos

Erschienen in: Investigational New Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Summary

This study evaluated the relevance of CXCR2 chemokine receptors in oral squamous cell carcinoma, by means of in vitro and in vivo approaches. The in vitro incubation of the selective and non-peptide CXCR2 receptor antagonist N-(2-hydroxy-4-nitrophenyl)-N9-(2-bromophenyl) Urea (SB225002; 25 to 800 nM) produced a time- and concentration-dependent inhibition of SCC158 (rat) and HN30 (human) cell lines viability. Conversely, this antagonist did not significantly affect the viability of the immortalized keratinocyte lineage, HaCaT. Additionally, the incubation of human IL-8 and rat CINC-1 CXCR2 agonists produced a concentration-related increase on HN30 and SCC158 proliferation. The submucosal injection of SCC158 cells (5 × 10⁶ cells) into the tongue of Fischer 344 rats induced tumor development, which displayed typical clinical features. Immunohistochemical analysis of rat tongue biopsies revealed a marked increase of CXCR2 receptor immunoreactivity, which was accompanied by augumented expression of VEGF and caspase-3. Our data suggests an important role for CXCR2 receptors in oral squamous cell carcinoma.

Al-Swiahb JN, Chen CH, Chuang HC, Fang FM, Tasi HT, Chien CY (2010) Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncol 6:837–850CrossRefPubMed

Chandu A, Smith ACH, Rogers SN (2006) Health-related quality of life in oral cancer: a review. J Oral Maxillofac Surg 64:495–502CrossRefPubMed

Massano J, Regateiro FS, Januário G, Ferreira A (2006) Oral squamous cell carcinoma :review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:67–76CrossRefPubMed

Rosenkilde MM, Schwartz TW (2004) The chemokine system – a major regulator of angiogenesis in health and disease. APMIS 112:481–495CrossRefPubMed

Charo IF, Ransohoff RM (2006) The many roles of chemokines and chamokine receptors in inflammation. N Engl J Med 354:610–621CrossRefPubMed

Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M (2006) LR + CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharm Ther 112:139–149CrossRef

Strieter BMD, Mestasa J, Gompertsc B, Keane MP, Belperio JA (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42:768–778CrossRefPubMed

Matzer SP, Zombou J, Sarau HM, llinghoff MR, Ulrich Beuscher H (2004) A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice. Immunobiology 209:225–233CrossRefPubMed

White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, Sarau HM (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095–10098CrossRefPubMed

10.

Kakinuma T, Hwang ST (2006) Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 4:639–651CrossRef

11.

Rollins BJ (2006) Inflammatory chemokines in cancer growth and progression. Eur J Cancer 42:760–767CrossRefPubMed

12.

Keeley EC, Mehrad B, Strieter RM (2010) CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106:91–111CrossRefPubMed

13.

Bernardi A, Jacques-Silva MC, Delgado-Cañedo A, Lenz G, Battastini AMO (2006) Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines. Eur J Pharmacol 532:214–222CrossRefPubMed

14.

Suzuki H, Mori M, Seto K, Shibata F, Nagahashi S, Kawaguchi C, Suzuki M, Matsui H, Watanabe K, Miura S, Ishii H (2000) Rat CXC chemokine GRO/CINC-1 paradoxically stimulates the growth of gastric epithelial cells. Aliment Pharmacol Ther 14(Suppl 1):94–100CrossRefPubMed

15.

Manjavachi MN, Quintão NL, Campos MM, Deschamps IK, Yunes RA, Nunes RJ, Leal PC, Calixto JB (2010) The effects of the selective and non-peptide CXCR2 receptor antagonist SB225002 on acute and long-lasting models of nociception in mice. Eur J Pain 14:23–31CrossRefPubMed

16.

Hasegawa H, Kano M, Hoshi N, Watanabe K, Satoh E, Nakayama B, Suzuki T (1998) An electrochemotherapy model for rat tongue carcinoma. J Oral Pathol Med 27:249–254CrossRefPubMed

17.

Nagamine K, Ozaki N, Shinoda M, Asai H, Nishiguchi H, Mitsudo K, Tohnai I, Ueda M, Sugiura Y (2006) Mechanical Allodynia and Thermal Hyperalgesia Induced by Experimental Squamous Cell Carcinoma of the Lower Gingiva in Rats. J Pain 7:659–670CrossRefPubMed

18.

Anneroth G, Batsakis JG, Luna M (1986) Malignancy grading of squamous cell carcinoma in the floor of the mouth related to clinical evaluation. Scand J Dent Res 94:347–358PubMed

19.

Wang B, Hendricks DT, Wamunyokoli F, Parker MI (2006) A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 66:3071–3077CrossRefPubMed

20.

Kim HE, Krug MA, Han I, Ensley J, Yoo GH, Forman JD, Kim HR (2000) Neutron radiation enhances cisplatin cytotoxicity independently of apoptosis in human head and neck carcinoma cells. Clin Cancer Res 6:4142–4147PubMed

21.

Deyrieux AF, Wilson VG (2007) In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line. Cytotechnology 54:77–83CrossRefPubMed

22.

Watanabe H, Iwase M, Ohashi M, Nagumo M (2002) Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 38:670–679CrossRefPubMed

23.

Christofakis EP, Miyazaki H, Rubink DS, Yeudall WA (2008) Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol 44:920–926CrossRefPubMed

24.

Wang B, Khachigian LM, Esau L, Birrer MJ, Zhao X, Parker MI, Hendricks DT (2009) A Key Role for Early Growth Response-1 and Nuclear Factor-κB in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer. Mol Cancer Res 7:755–764CrossRefPubMed

25.

Liu Z, Yang L, Xu J, Zhang X, Wang B (2011) Enhanced Expression and Clinical Significance of Chemokine Receptor CXCR2 in Hepatocellular Carcinoma. J Surg Res 166:241–246CrossRefPubMed

26.

Varney ML, Johansson SL, Singh RK (2006) Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 125:209–216PubMed

27.

Sharma B, Singh S, Varney ML, Singh RK (2010) Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets 14:435–442CrossRefPubMed

28.

Tse GM, Chan AWH, Yu KH, King AD, Wong KT, Chen GG, Tsang RKY, Chan ABW (2007) Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma. Ann Surg Oncol 14:3558–3565CrossRefPubMed

29.

Choi S, Myers JN (2008) Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy. J Dent Res 87:14CrossRefPubMed

30.

Sappayatosok K, Maneerat Y, Swasdison S, Viriyavejakul P, Dhanuthai K, Zwang J, Chaisri U (2009) Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation. Med Oral Patol Oral Cir Bucal 14:319–324

31.

Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S (2004) CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25:201–209CrossRefPubMed

32.

Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, Nunez G, Polverini PJ, Nör JE (2005) Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 65:5063–5069CrossRefPubMed

33.

Petreaca ML, Yao M, Liu Y, DeFea K, Martins-Green M (2007) Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8 (IL-8/CXCL8) Is Required for IL-8/CXCL8-induced Endothelial Permeability. Mol Biol Cell 18:5014–5023CrossRefPubMed

34.

Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16:3875–3886CrossRefPubMed

35.

Zhang HY, Meng X, Du ZX, Fang CQ, Liu GL, Wang HQ, Deng WW (2009) Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin Exp Med 9:207–213CrossRefPubMed

36.

Sitorus RS, Gumay S, van der Valk P (2009) The apoptotic paradox in retinoblastoma. Ann N Y Acad Sci 1171:77–86CrossRefPubMed

37.

Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW (2009) Clinical significance of stromal apoptosis in colorectal cancer. Br J Cancer 101:765–773CrossRefPubMed

Titel: The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma
verfasst von: Juliana Romanini
Tânia R. Mielcke
Paulo C. Leal
Cláudia P. Figueiredo
João B. Calixto
Fernanda B. Morrone
Eraldo L. Batista Jr
Maria M. Campos
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 4/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-011-9701-x

Springer Medizin

The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia

Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie